Immediate Impact
58 standout
Citing Papers
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Digestive cancers: mechanisms, therapeutics and management
2025 Standout
Works of Cyril Abdeddaim being referenced
Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.
2021
Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Cyril Abdeddaim | 281 | 163 | 79 | 173 | 30 | 489 | |
| Toshiko Minamoto | 250 | 126 | 65 | 155 | 34 | 521 | |
| Maria-Pilar Barretina-Ginesta | 225 | 217 | 61 | 181 | 31 | 470 | |
| Dominique Berton | 346 | 164 | 78 | 74 | 32 | 449 | |
| P. Iyengar | 152 | 128 | 104 | 147 | 22 | 507 | |
| Albert J. Bonebrake | 233 | 194 | 71 | 223 | 22 | 507 | |
| Lucia Musacchio | 261 | 183 | 48 | 147 | 41 | 493 | |
| Edmonson Jh | 246 | 197 | 99 | 103 | 27 | 560 | |
| S. Loibl | 249 | 221 | 141 | 92 | 29 | 499 | |
| Erin K. Crane | 189 | 192 | 122 | 147 | 36 | 500 | |
| Josep M. del Campo | 185 | 261 | 62 | 79 | 20 | 436 |
All Works
Loading papers...